Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-11-04 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
BEYFORTUS (NIRSEVIMAB) APPROVED IN EU
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Beyfortus (nirsevimab) in the EU, including clinical trial results, regulatory designations, and commercial agreements. The document is not an annual or quarterly financial report, nor is it an earnings release or a call transcript. It is a regulatory filing providing material information about a product approval and related clinical data. The document length is about 15,000 characters, and it is a standalone filing rather than an announcement of a report publication. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-11-04 English
Beyfortus (nirsevimab) approved in EU
Regulatory Filings Classification · 97% confidence The document begins with an 'RNS Number' and a timestamp, indicating it is a regulatory announcement. The content details the European Commission's approval of the drug Beyfortus (nirsevimab) for RSV prevention. This is a specific, material event announcement concerning regulatory status and product development, not a comprehensive annual report (10-K), a quarterly report (IR), or a general earnings release (ER). Since it is a formal announcement of a regulatory decision/approval, it fits best under the general 'Regulatory Filings' category (RNS), as it is not covered by more specific codes like DIV, CAP, or MANG. Although it is a significant announcement, RNS serves as the appropriate catch-all for material regulatory news that isn't a financial statement or a call transcript.
2022-11-04 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of a specific date, providing details on issued share capital and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The document is relatively short (3180 characters) and primarily serves as a notification of voting rights rather than a full report or detailed financial disclosure. It does not contain financial statements, management discussion, or audit information. Given these characteristics, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service). It explicitly states the notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The content details the total number of voting rights and the issued share capital as of a specific date (October 31, 2022). This type of regulatory disclosure regarding voting rights and capital structure is a specific regulatory announcement. While it relates to capital, it is not a financing activity (CAP) or a share issue (SHA), but rather a mandatory disclosure of the current voting denominator. Since it is a general regulatory announcement provided through RNS that doesn't fit the more specific categories like DVA (Voting Results) or DIRS (Director's Dealing), the most appropriate classification is the general regulatory filing category, RNS.
2022-11-01 English
CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the positive results from the CAPItello-291 Phase III trial of capivasertib in breast cancer. The document includes clinical trial results, drug information, and company background. It is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing reporting significant clinical trial results and related corporate information. The document length is over 12,000 characters and contains substantive content, not just an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-10-26 English
Capivasertib Phase III trial met primary endpoints
Regulatory Filings Classification · 98% confidence The document is a press release issued via RNS (RNS Number: 1531E) on October 26, 2022, announcing positive Phase III trial results for a drug combination (Capivasertib plus Faslodex) in advanced breast cancer. It contains key financial/clinical results, quotes from management, and notes on the trial methodology. This structure strongly indicates an Earnings Release (ER) or a general announcement of significant news. Since it focuses on clinical trial results and business updates rather than just preliminary financial figures, and it is distributed via RNS, it fits best as an Earnings Release (ER) which often includes major operational/clinical milestones, or potentially a Regulatory Filing (RNS) if it were shorter. Given the length (12,142 chars) and comprehensive nature of the announcement detailing trial endpoints, safety profiles, and future plans (presenting data at a medical meeting), it is classified as an Earnings Release (ER) as it communicates the period's key performance/development news, even if not strictly quarterly financials. It is not a short announcement pointing to an attached report (RPA).
2022-10-26 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.